Abstract: The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomerulosclerosis as well as secondary Raynaud's syndrome.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
July 4, 2017
Assignee:
SINOXA PHARMA GMBH
Inventors:
Rudolf Reiter, Johannes Tack, Reinhard Horowski
Abstract: The present invention relates to the use of 5-HT2 receptor antagonists and in particular of 8-?-ergolines such as lisuride, terguride and the derivatives thereof as 5-HT2B and 5-HT2A receptor antagonists and antioxidants in preferably higher-dosed and preferably continuous use for the treatment, progression prophylaxis and general prophylaxis of organ fibroses and other pathological organ remodeling caused by mesenchymal proliferation
Type:
Application
Filed:
September 22, 2014
Publication date:
March 12, 2015
Applicant:
SINOXA PHARMA GMBH
Inventors:
Reinhard HOROWSKI, Heinz PALLA, Johannes TACK
© 2024 Justia
